Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switching From Intravenous (IV) to Subcutaneous (SC) Vedolizumab in University Hospital Center Osijek
N/A
Inflammatory bowel disease consists of ulcerative colitis (UC) or Crohn's d...
Status
Completed
Location
Klinički bolnički centar Osijek (University Hospital Center Osijek)
Start Date
2022-05-01
Trial ID
NCT05504915
Effectiveness and Tolerance of IV vs SC Biological Drugs in Gastrointestinal Diseases
N/A
Biologics are effective pharmacological treatments for Inflammatory Bowel D...
Status
Recruiting
Location
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC CEMAD
Start Date
2023-09-04
Trial ID
NCT06604728
A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants
PHASE1
The purpose of this study is to assess the PK of vedolizumab following a si...
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
N/A
The goal of this observational study is to assess the feasibility and effec...
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
PHASE3
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes...
Status
Active Not Recruiting
Location
Gastro Health Research - St. Vincent'S East /ID# 275089